Continuous Glucose Monitoring for Diabetes in Hemodialysis Patients
(DEXCOM-HD Trial)

Recruiting in Palo Alto (17 mi)

Overseen byConnie Rhee, MD, MSc

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of California, Irvine

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a pilot study enrolling adult hemodialysis patients with diabetes recruited from the University of California Irvine Medical Center (UCIMC) who will undergo simultaneous measurement of glucose levels using 1) continuous glucose monitor (CGM) measured by a Dexcom G6 device vs. 2) "gold-standard" blood glucose levels using capillary fingerstick or venous blood glucose measurements obtained on a point of care (POC) blood glucose meter. The study will assess Dexcom G6 accuracy by comparing glucose levels on the CGM device vs. blood glucose measurements in the study population.

Research Team

Connie Rhee, MD, MSc

Principal Investigator

Faculty

Eligibility Criteria

This trial is for adults over 18 who are on hemodialysis due to kidney issues and also have diabetes. They must be patients at the University of California Irvine Medical Center with an expected hospital stay of at least 48 hours and can give informed consent.

Inclusion Criteria

Adult hemodialysis patients age 18 years or older

Have a comorbidity of diabetes

Receipt of care from the inpatient University of California Irvine Medical Center nephrology consult service

See 2 more

Treatment Details

Interventions

Dexcom G6 Continuous Glucose Monitor (Continuous Glucose Monitor)

Trial OverviewThe study tests how well the Dexcom G6 Continuous Glucose Monitor tracks blood sugar levels compared to standard fingerstick or venous blood glucose measurements in hemodialysis patients with diabetes.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Dexcom G6 Continuous Glucose MonitorExperimental Treatment1 Intervention